FDA approves epidiolex for epilepsy

Rajalaxmi Natarajan, PhD
Tue, 06/26/2018

The Food and Drug Administration (FDA) has approved epidiolex, made of cannabidiol (CBD) and derived from marijuana plant to treat Dravet Syndrome and Lennox-Gestaut Syndrome, rare childhood-onset forms of epilepsy. Epidiolex, marketed by GW Pharmaceuticals Plc is the first cannabis-based drug to receive FDA approval. This decision could encourage more research into the medicinal properties of cannabis to treat other epileptic conditions.